Press Releases

Date Title
Toggle Summary Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
Four of the first six HRAS mutant HNSCC patients enrolled on study achieve confirmed RECIST partial responses Durable responses greater than one year observed SAN DIEGO , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical stage biopharmaceutical company focused on the
Toggle Summary Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference
SAN DIEGO , Aug. 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will participate in a
Toggle Summary Kura Oncology Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Aug. 10, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 7,700,000 shares of its common stock at a
Toggle Summary Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions,
Toggle Summary Kura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study
Tipifarnib demonstrates high level of clinical activity and durable partial responses in ongoing Phase 2 trial in HRAS mutant squamous cell head and neck cancers Management to host webcast and conference call today at 4:30 p.m. EDT LA JOLLA, Calif. , Aug.
Toggle Summary Kura Oncology to Report Second Quarter 2017 Financial Results
LA JOLLA, Calif. , July 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report second quarter 2017 financial results after the close of U.S.
Toggle Summary Kura Oncology Announces Issuance of U.S. Patent for Lead Product Candidate Tipifarnib in Head and Neck Cancer
New Patent Provides Exclusivity to 2036 SAN DIEGO , July 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the United States Patent and Trademark Office has
Toggle Summary Kura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS Mutant Head and Neck Cancer
SAN DIEGO , July 13, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced it has entered into a collaboration agreement with Foundation Medicine, Inc.
Toggle Summary Kura Oncology Added to Russell 3000® Index
LA JOLLA, Calif. , June 26, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been added to the broad U.S.
Toggle Summary Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
LA JOLLA, Calif. , June 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that clinical and preclinical data for tipifarnib in the treatment of relapsed or